Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer

TAMPA and LONDON, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today announced the appointment of Kameel D. Farag as its Interim Chief Financial Officer who joined Akari last month. Mr. Farag is a proven biotech and global finance executive with a track record spanning over two decades of scaling innovative biotech companies through transformational growth.

Read more at globenewswire.com